<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Enzymatic activity responsible for the cleavage of <z:chebi fb="0" ids="24500">heparan</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi>, commonly known as heparanase, is abundant in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-derived cells </plain></SENT>
<SENT sid="1" pm="."><plain>Heparanase cleaves <z:chebi fb="0" ids="24500">heparan</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> side chains, presumably at sites of low sulfation, thus facilitating structural alterations of the extracellular matrix and basement membrane underlying epithelial and endothelial cells </plain></SENT>
<SENT sid="2" pm="."><plain>Traditionally, heparanase activity was correlated with the metastatic potential of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-derived cells, attributed to enhanced cell dissemination as a consequence of <z:chebi fb="0" ids="24500">heparan</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> cleavage and remodeling of the extracellular matrix barrier </plain></SENT>
<SENT sid="3" pm="."><plain>More recently, heparanase upregulation was documented in an increasing number of human <z:mp ids='MP_0002038'>carcinomas</z:mp> and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, correlating with increased <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e>, vascular density, and shorter post-operative survival of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Although heparanase upregulation and its pro-malignant features are well documented, the instance of its induction in the course of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development was less investigated </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we used immunohistochemical analysis to investigate heparanase expression in <z:mpath ids='MPATH_458'>normal</z:mpath> esophagus, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the esophagus </plain></SENT>
<SENT sid="6" pm="."><plain>We report that heparanase expression is already induced in Barrett's epithelium without <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and is further increased during progression through distinct pathological stages, namely, low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Notably, heparanase induction correlated with <z:mp ids='MP_0000351'>increased cell proliferation</z:mp> index revealed by Ki-67 staining </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that heparanase function is not limited to the process of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">tumor metastasis</z:e>, but rather is engaged at the early stages of esophagus <z:mp ids='MP_0002038'>carcinoma</z:mp> initiation and progression </plain></SENT>
</text></document>